Vicki L. Sato Sells 1,666 Shares of Denali Therapeutics Inc. (NASDAQ:DNLI) Stock

Denali Therapeutics Inc. (NASDAQ:DNLI) Director Vicki L. Sato sold 1,666 shares of the company’s stock in a transaction on Monday, April 15th. The shares were sold at an average price of $18.29, for a total value of $30,471.14. Following the completion of the sale, the director now owns 118,043 shares of the company’s stock, valued at approximately $2,159,006.47. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Denali Therapeutics Trading Down 1.3 %

NASDAQ:DNLI opened at $16.60 on Friday. The firm has a market capitalization of $2.31 billion, a price-to-earnings ratio of -15.37 and a beta of 1.33. Denali Therapeutics Inc. has a 1-year low of $15.45 and a 1-year high of $33.31. The business’s fifty day moving average price is $19.26 and its 200 day moving average price is $19.25.

Denali Therapeutics (NASDAQ:DNLI) last posted its quarterly earnings results on Tuesday, February 27th. The company reported ($0.86) earnings per share for the quarter, missing the consensus estimate of ($0.81) by ($0.05). Denali Therapeutics had a negative net margin of 36.51% and a negative return on equity of 13.50%. During the same period last year, the business earned ($0.75) EPS. Equities analysts forecast that Denali Therapeutics Inc. will post -2.62 earnings per share for the current year.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. PNC Financial Services Group Inc. increased its position in Denali Therapeutics by 85.2% in the 4th quarter. PNC Financial Services Group Inc. now owns 1,669 shares of the company’s stock worth $46,000 after purchasing an additional 768 shares during the last quarter. CWM LLC increased its position in Denali Therapeutics by 216.7% in the 4th quarter. CWM LLC now owns 2,011 shares of the company’s stock worth $43,000 after purchasing an additional 1,376 shares during the last quarter. Assetmark Inc. increased its position in Denali Therapeutics by 49.1% in the 3rd quarter. Assetmark Inc. now owns 2,148 shares of the company’s stock worth $44,000 after purchasing an additional 707 shares during the last quarter. KBC Group NV acquired a new position in Denali Therapeutics in the 4th quarter worth about $53,000. Finally, Sandia Investment Management LP acquired a new position in Denali Therapeutics in the 4th quarter worth about $70,000. 92.92% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of brokerages have recently issued reports on DNLI. HC Wainwright cut their target price on Denali Therapeutics from $105.00 to $95.00 and set a “buy” rating on the stock in a research report on Wednesday, February 28th. The Goldman Sachs Group cut their target price on Denali Therapeutics from $73.00 to $50.00 and set a “buy” rating on the stock in a research report on Thursday, February 29th. Wedbush reaffirmed an “outperform” rating and set a $31.00 target price on shares of Denali Therapeutics in a research report on Wednesday, February 28th. Finally, UBS Group cut their target price on Denali Therapeutics from $70.00 to $32.00 and set a “buy” rating on the stock in a research report on Tuesday, April 9th. Eight research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Denali Therapeutics has an average rating of “Buy” and an average price target of $41.22.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.